News

The Pediatric Emergency Medicine and Pediatric Hematology/Oncology divisions at MUSC have joined forces to create and test an ...
For 21 years, Sebastien Beauzile lived with the chronic pain of sickle cell anemia. Now, thanks to a groundbreaking genetic treatment, he is the first person in New York to be cured of the disease.
Children with sickle cell disease, a chronic hemolytic anemia, present with a wide variety of neurological syndromes, including ischemic and hemorrhagic stroke, transient ischemic attacks ...
Vertex Pharma's £1.65 million ($2.05 million) gene-editing therapy for sickle cell disease (SCD), Casgevy, has been given the green light for use by the NHS in England under a managed access ...
Race has no biological basis and no effect on the onset or progression of disease.
Pfizer is voluntarily withdrawing its sickle cell disease (SCD) therapy Oxbryta from all world markets after finding an "imbalance" in deaths in its clinical trials programme. It's a blow to the ...
Sickle cell is one of the diseases in Kenya that is surrounded by many misconceptions and cultural beliefs A group of survivors of the disease from Kakamega have, however, embarked on a mission to ...
WEST MONROE, La. (KTVE/KARD) — Today on Louisiana Living, Ashley Doughty is joined by Lonnikia Robinson to describe the upcoming Walk-A-Thon. For more information, watch the video above ...
Sickle cell disease is an autosomal recessive blood disorder that can lead to anaemia. It is caused by a mutation in the haemoglobin gene, which leads to deformation of red blood cells.
These states represent about 84% of Medicaid beneficiaries with sickle cell disease. Insurers, however, are wary broadly of the financial costs associated with cell and gene therapies, a report ...
Mutations in FANCX appear to cause a lethal form of Fanconi anemia, a finding that sheds light ... a preliminary report on FAAP100 mutations in cell samples taken from a fetus four years earlier ...
KJ Muldoon came into the world with a genetic time bomb ticking inside him.